Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Schering-Plough's once-daily outdoor allergies tablets, Clarinex-D 24-hour, for the relief of nasal and non-nasal symptoms, including nasal congestion, in patients 12 years of age and older.
Subscribe to our email newsletter
The approval makes Clarinex-D 24-hour (desloratadine 5mg and pseudoephedrine sulfate USP 240mg) extended release tablets available in time for the spring allergy season. Clarinex-D 24-hour will be the only once-daily prescription antihistamine and decongestant combination treatment on the market to provide 24-hour relief of nasal and non-nasal allergy symptoms.
The product uses a gel control system to control the release of the pseudoephedrine component for consistent delivery. This ensures once-daily 24-hour efficacy, which allows people to wake up with their symptoms under control.
The approval is based on results from two two-week clinical trials involving 2,852 patients with seasonal allergic rhinitis, 708 of whom received Clarinex-D 24-hour. In both trials, the antihistaminic efficacy of Clarinex-D 24-hour, in symptoms of allergic rhinitis excluding nasal congestion, was significantly greater than pseudoephedrine or Clarinex 5mg alone. Furthermore, the decongestant efficacy of Clarinex-D 24-hour, when measured by nasal congestion, was significantly greater than desloratadine.